Observational analysis reveals hygromycin B induces secondary metabolite production in fungal taxa, suggesting wide applicability.
Hygromycin B, a well-known antibiotic agent, was recently reported as an inducer of secondary metabolites for a fungal strain of Fusarium sp. In this study, we verified the versatility and usefulness of hygromycin B as an inducer of fungal secondary metabolite production. We demonstrate that hygromycin B induces the production of various fungal secondary metabolites, including polyketides, peptides, and terpenes, in 71% of 28 fungal strains belonging to the Ascomycota phylum, specifically within the Eurotiomycetes, Sordariomycetes, and Dothideomycetes classes. We also demonstrate the discovery of novel compounds, named hannocateol (1) and shirazines A (2) and B (3), from the hygromycin B-supplemented cultured materials. The production of the novel compounds increased with hygromycin B-supplementation up to 100 μg/g (maximum >100-fold) but not by HDAC inhibitors, protein synthesis inhibitors against prokaryotes, and antifungal agents. Notably, protein synthesis inhibitors against eukaryotes similar to hygromycin B, such as 5-fluorouracil and paromomycin, could induce the production of 1 and 2, suggesting that its mechanism would be associated with protein synthesis inhibition. We proved that hygromycin B is a highly versatile inducer of secondary metabolite production applicable across diverse fungal taxa, making it a simple and powerful tool for uncovering cryptic biosynthetic pathways and discovering novel bioactive compounds.
No takes yet. Share an insight, caveat, or question.
Kato et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: